Clinical Considerations for COVID-19 Vaccination
The Advisory Committee on Immunization Practices (ACIP) has issued interim recommendations for the use of Pfizer-BioNTech and Moderna COVID-19 vaccines for the prevention of coronavirus disease 2019 (COVID-19) in the United States. You can find these recommendations as well as clinical considerations for managing adverse events below.
Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States
Interim considerations: Preparing for the potential management of anaphylaxis at COVID-19 vaccination sites
Lab tests to collect shortly after severe allergic reaction (e.g., anaphylaxis) following COVID-19 vaccination